A roadmap to parathyroidectomy for kidney transplant candidates
Open Access
- 23 February 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 15 (8) , 1459-1474
Abstract
Chronic kidney disease mineral and bone disorder may persist after successful kidney transplantation. Persistent hyperparathyroidism has been identified in up to 80% of patients throughout the first year after kidney transplantation. International guidelines lack strict recommendations about the management of persistent hyperparathyroidism. However, it is associated with adverse graft and patient outcomes, including higher fracture risk and an increased risk of all-cause mortality and allograft loss. Secondary hyperparathyroidism may be treated medically (vitamin D, phosphate binders and calcimimetics) or surgically (parathyroidectomy). Guideline recommendations suggest medical therapy first but do not clarify optimal parathyroid hormone targets or indications and timing of parathyroidectomy. There are no clear guidelines or long-term studies about the impact of hyperparathyroidism therapy. Parathyroidectomy is more effective than medical treatment, although it is associated with increased short-term risks. Ideally parathyroidectomy should be performed before kidney transplantation to prevent persistent hyperparathyroidism and improve graft outcomes. We now propose a roadmap for the management of secondary hyperparathyroidism in patients eligible for kidney transplantation that includes the indications and timing (pre- or post-kidney transplantation) of parathyroidectomy, the evaluation of parathyroid gland size and the integration of parathyroid gland size in the decision-making process by a multidisciplinary team of nephrologists, radiologists and surgeons.Keywords
This publication has 137 references indexed in Scilit:
- Recovery Versus Persistence of Disordered Mineral Metabolism in Kidney Transplant RecipientsSeminars in Nephrology, 2013
- Clinicopathological Analysis of Persistent Hypercalcemia and Hyperparathyroidism After Kidney Transplantation in Long‐Term Dialysis PatientsTherapeutic Apheresis and Dialysis, 2013
- Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing DialysisNew England Journal of Medicine, 2012
- Does Contrast-Enhanced Cervical Ultrasonography Improve Preoperative Localization Results in Patients With Sporadic Primary Hyperparathyroidism?Journal of Clinical Imaging Science, 2012
- Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney diseaseKidney International, 2011
- Elevated Fibroblast Growth Factor 23 is a Risk Factor for Kidney Transplant Loss and MortalityJournal of the American Society of Nephrology, 2011
- Clinical Impact of Hypercalcemia in Kidney TransplantInternational Journal of Nephrology, 2011
- Secondary and Tertiary Hyperparathyroidism, State of the Art Surgical ManagementSurgical Clinics of North America, 2009
- Progression of Coronary Artery Calcification in Renal Transplantation and the Role of Secondary Hyperparathyroidism and InflammationClinical Journal of the American Society of Nephrology, 2009
- Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric TransplantNew England Journal of Medicine, 1999